NCT01334697Unknown1 期
Phase I, Randomized, Multicenter, Double-blind, Single Dose, Dose-Escalation, Placebo-Controlled, Parallel Group Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetics of Intravenous Administration of Cardiotrophin-1 (CT-1)in Healthy Volunteers
Digna Biotech S.L.2 个研究点 分布在 1 个国家目标入组 33 人开始时间: 2012年11月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 发起方
- 入组人数
- 33
- 试验地点
- 2
- 主要终点
- Number of participants with Adverse Events as a Measure of Safety and Tolerability
研究概览
简要总结
The general aim of the study is to determinate safety, tolerability and early pharmacokinetics of cardiotrophin.1 in healthy volunteers.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Male or Female, between the ages of 18 and
- •Healthy condition (no suffering from known acute or chronic disease)
- •No clinically important abnormal physical or laboratory findings at the screening examination.
- •Normal or clinically acceptable ECG.
- •Normal blood pressure (systolic: 90-140 mmHg; diastolic: 50-90 mmHg) and heart rate (40-100 bpm).
- •Body Mass Index of 19.0-29.0 (kg/m2).
- •Ability to communicate well with the investigator and to comply with the requirements of the entire study.
- •Willingness to give written informed consent (prior to any study-related procedures being performed) and to be able to adhere to the study restrictions and examination schedule.
- •For female subjects with childbearing potential: use of a known highly effective method of birth control, defined as those which results in a low failure rate: i.e. less 1% per year, (contraceptive pills, intrauterine contraceptive device, implants, vasectomized partner or sexual abstinence), for at least three consecutive months prior to the study, during the study and one month after the end of the study.
- •For male subjects with partners of child bearing potential: use of appropriate contraceptive methods (vasectomy, condoms or sexual abstinence), for at least the study period and one month after the end of the study.
排除标准
- •Administration of any investigational drug in the period within three months prior to informed consent.
- •Use of any prescription medication during the period 0 to 30 days or over-the-counter medication during the 0 to 5 days before entry to the study.
- •Donation or loss of greater than 400 ml of blood in the period 0 to 12 weeks before entry to the study.
- •Serious adverse reaction or hypersensitivity to any drug.
- •Inability to communicate or co-operate with the investigator because of a language problem, poor mental development or impaired cerebral function.
- •History of drug dependence (except tobacco) or psychiatric illness within the past 2 years.
- •Consumption of alcohol within 24 hours prior to dose administration.
- •Presence of pain incurred by unknown causes.
- •Pregnancy or nursing.
- •Positive urine drug screen for drugs with a high potential for abuse and low persistence in the urine.
- •Inability to refrain from smoking during study days.
- •Any other condition which, in the opinion of the investigators, is likely to interfere with the successful collection of the measures required for the study.
研究组 & 干预措施
Cardiotrophin-1
Experimental
干预措施: recombinant human cardiotrophin-1 (Drug)
Placebo
Placebo Comparator
干预措施: Placebo (Other)
结局指标
主要结局
Number of participants with Adverse Events as a Measure of Safety and Tolerability
时间窗: single dose administration (baseline) and 1 post-treatment follow up week
Evaluate the tolerability and safety of single dose intravenous administration
次要结局
- Pharmacokinetic and Pharmacodynamic parameters(single adminsitration (baseline) and 1 week of follow up)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
A Clinical Trial of CS12192 in Healthy SubjectsHealthyNCT05922709Chipscreen Biosciences, Ltd.108
已完成
1 期
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic Profiles and Food Effect of CS32582 CapsulesHealthyNCT06224595Chipscreen Biosciences, Ltd.112
已完成
1 期
AZD5423 Single Ascending Dose StudyHealthy VolunteersNCT00963183AstraZeneca72
已完成
1 期
AZD8683 Single Ascending Dose StudyHealthy VolunteersNCT00979849AstraZeneca130
已完成
1 期
AZD5423 Multiple Ascending Dose StudyHealthyNCT01037504AstraZeneca27